This includes an ongoing phase II clinical trial with an oncolytic adenovirus (DNX-2401) combined with pembrolizumab (anti–PD-1) for patients with recurrent GBM (ClinicalTrials.gov NCT02798406). The gene discussed is PDCD1; the disease is glioblastoma.